182 related articles for article (PubMed ID: 28166648)
1. Characteristics of Minimally Oversized Adeno-Associated Virus Vectors Encoding Human Factor VIII Generated Using Producer Cell Lines and Triple Transfection.
Nambiar B; Cornell Sookdeo C; Berthelette P; Jackson R; Piraino S; Burnham B; Nass S; Souza D; O'Riordan CR; Vincent KA; Cheng SH; Armentano D; Kyostio-Moore S
Hum Gene Ther Methods; 2017 Feb; 28(1):23-38. PubMed ID: 28166648
[TBL] [Abstract][Full Text] [Related]
2. A versatile adeno-associated virus vector producer cell line method for scalable vector production of different serotypes.
Yuan Z; Qiao C; Hu P; Li J; Xiao X
Hum Gene Ther; 2011 May; 22(5):613-24. PubMed ID: 21186998
[TBL] [Abstract][Full Text] [Related]
3. The Immune Response to the fVIII Gene Therapy in Preclinical Models.
Patel SR; Lundgren TS; Spencer HT; Doering CB
Front Immunol; 2020; 11():494. PubMed ID: 32351497
[TBL] [Abstract][Full Text] [Related]
4. Comparative transcriptomic and proteomic kinetic analysis of adeno-associated virus production systems.
Lin YC; Lu M; Cai W; Hu WS
Appl Microbiol Biotechnol; 2024 Jun; 108(1):385. PubMed ID: 38896252
[TBL] [Abstract][Full Text] [Related]
5. Vector integration and fate in the hemophilia dog liver multiple years after AAV-FVIII gene transfer.
Batty P; Fong S; Franco M; Sihn CR; Swystun LL; Afzal S; Harpell L; Hurlbut D; Pender A; Su C; Thomsen H; Wilson C; Youssar L; Winterborn A; Gil-Farina I; Lillicrap D
Blood; 2024 Jun; 143(23):2373-2385. PubMed ID: 38452208
[TBL] [Abstract][Full Text] [Related]
6. Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.
Samelson-Jones BJ; Arruda VR
Front Immunol; 2020; 11():618. PubMed ID: 32425925
[TBL] [Abstract][Full Text] [Related]
7. A Scalable and Accurate Method for Quantifying Vector Genomes of Recombinant Adeno-Associated Viruses in Crude Lysate.
Ai J; Ibraheim R; Tai PWL; Gao G
Hum Gene Ther Methods; 2017 Jun; 28(3):139-147. PubMed ID: 28488944
[TBL] [Abstract][Full Text] [Related]
8. Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing.
Selvaraj N; Wang CK; Bowser B; Broadt T; Shaban S; Burns J; Saptharishi N; Pechan P; Golebiowski D; Alimardanov A; Yang N; Mitra G; Vepachedu R
Hum Gene Ther; 2021 Aug; 32(15-16):850-861. PubMed ID: 33397196
[TBL] [Abstract][Full Text] [Related]
9. Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery.
Brown HC; Wright JF; Zhou S; Lytle AM; Shields JE; Spencer HT; Doering CB
Mol Ther Methods Clin Dev; 2014; 1():14036. PubMed ID: 26015976
[TBL] [Abstract][Full Text] [Related]
10. Factor VIII delivered by haematopoietic stem cell-derived B cells corrects the phenotype of haemophilia A mice.
Ramezani A; Zweier-Renn LA; Hawley RG
Thromb Haemost; 2011 Apr; 105(4):676-87. PubMed ID: 21264447
[TBL] [Abstract][Full Text] [Related]
11. Hemophilia Healing with AAV: Navigating the Frontier of Gene Therapy.
Khan SU; Khan MU; Suleman M; Inam A; Din MAU
Curr Gene Ther; 2024; 24(4):265-277. PubMed ID: 38284735
[TBL] [Abstract][Full Text] [Related]
12. AAV mediated repression of Neat1 lncRNA combined with F8 gene augmentation mitigates pathological mediators of joint disease in haemophilia.
Sarangi P; Senthilkumar MB; Amit S; Kumar N; Jayandharan GR
J Cell Mol Med; 2024 Jun; 28(11):e18460. PubMed ID: 38864710
[TBL] [Abstract][Full Text] [Related]
13. Cellular stress and coagulation factor production: when more is not necessarily better.
Chen Z; Herzog RW; Kaufman RJ
J Thromb Haemost; 2023 Dec; 21(12):3329-3341. PubMed ID: 37839613
[TBL] [Abstract][Full Text] [Related]
14. AAV's anatomy: roadmap for optimizing vectors for translational success.
Mitchell AM; Nicolson SC; Warischalk JK; Samulski RJ
Curr Gene Ther; 2010 Oct; 10(5):319-340. PubMed ID: 20712583
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging gene therapies for haemophilia A and B.
Kaczmarek R; Miesbach W; Ozelo MC; Chowdary P
Haemophilia; 2024 Apr; 30 Suppl 3():12-20. PubMed ID: 38528615
[TBL] [Abstract][Full Text] [Related]
16. Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond.
Valdmanis PN; Kay MA
Hum Gene Ther; 2017 Apr; 28(4):361-372. PubMed ID: 28073291
[TBL] [Abstract][Full Text] [Related]
17. Tuning capsid formation dynamics in recombinant adeno-associated virus producing synthetic cell lines to enhance full particle productivity.
Lu M; Lin YC; Kuo HJ; Cai W; Ye Q; Zhao L; Hu WS
Biotechnol J; 2024 Mar; 19(3):e2400051. PubMed ID: 38479988
[TBL] [Abstract][Full Text] [Related]
18. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.
Leavitt AD; Konkle BA; Stine KC; Visweshwar N; Harrington TJ; Giermasz A; Arkin S; Fang A; Plonski F; Yver A; Ganne F; Agathon D; Resa MLA; Tseng LJ; Di Russo G; Cockroft BM; Cao L; Rupon J
Blood; 2024 Feb; 143(9):796-806. PubMed ID: 37871576
[TBL] [Abstract][Full Text] [Related]
19. Genetic fate of recombinant adeno-associated virus vector genomes in muscle.
Schnepp BC; Clark KR; Klemanski DL; Pacak CA; Johnson PR
J Virol; 2003 Mar; 77(6):3495-504. PubMed ID: 12610125
[TBL] [Abstract][Full Text] [Related]
20. Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene.
Rashnonejad A; Chermahini GA; Li S; Ozkinay F; Gao G
Mol Biotechnol; 2016 Jan; 58(1):30-6. PubMed ID: 26607476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
